Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject must be at least 18 years of age.
Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.
Subjects with moderately to severely active UC based on Mayo score criteria.
Subjects must have failed or be intolerant of at least one of the following treatments for UC:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
547 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal